Drug Profile
Pitavastatin - Kowa
Alternative Names: Alipza; Itavastatin; Livalo; Livazo; Nisvastatin; NK 104; NK-104-CR; NK-104-LH; NK-104-PH; NKS 104; P 872441; Pitavastatin Calcium; Redevant; Trolise; VezepraLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Nissan Chemical Industries; ViiV Healthcare
- Developer AbbVie; Algorithm; Daiichi Sankyo Company; Eli Lilly and Company; ESTEVE; JW Pharmaceutical; Kowa; Mitsubishi Tanabe Pharma Corporation; Nissan Chemical Industries; Recordati
- Class Antihyperlipidaemics; Carboxylic acids; Cyclopropanes; Fluorobenzenes; Quinolines; Small molecules
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Dyslipidaemias; Hypercholesterolaemia; Hyperlipidaemia
- Registered Hyperlipoproteinaemia type IIa
- Phase III Cardiovascular disorders
- Discontinued Alzheimer's disease
Most Recent Events
- 31 Jul 2023 National Institutes of Health's National Heart, Lung and Blood Institute in collaboration with AIDS Clinical Trials Group (ACTG) completes phase-III REPRIEVE trial in Cardiovascular disorders in Zimbabwe, Uganda, Thailand, Spain, South Africa, Puerto Rico, Peru, India, Haiti, Canada, Brazil, Botswana, USA (PO) (NCT02344290)
- 23 Jul 2023 Efficacy and adverse events data from a phase III REPRIEVE trial in Cardiovascular disorders released by the AIDS Clinical Trials Group (ACTG)
- 19 Feb 2023 Pharmacodynamics data from a phase III REPRIEVE trial in Cardiovascular disorders presented at the 30th Conference on Retroviruses and Opportunistic Infections (CROI-2023)